Business Blockbuster - Helpng business to be more visible on Google

Business Daily Media


.

Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore

New state-of-the-art facility to develop immunotherapy assets to address unmet needs in cancer treatment

SINGAPORE - Media OutReach - 28 June 2023 – Biosyngen, an immuno-oncology company with technology targeting the unmet medical needs in solid tumour and lymphoma treatment, today announced the official opening of its latest Good Manufacturing Practice (GMP) facility in Singapore.

The facility will support cell manufacturing for immunotherapies in Singapore and across the world, and create more than 200 jobs for the cell and gene therapy (CGT) industry in the next three to five years.

[From Left to Right] Dr Han Deping, Chief Medical Officer, Biosyngen; Dr Cheong Wei Yang, Deputy Secretary (Technology), Ministry of Health; Ms Joan Zhang, Chairman, Biosyngen; Mr Alvin Tan, Minister of State for the Ministry of Trade & Industry; Ms Lily Peng Yuemei, Deputy Party Secretary, Director, Knowledge City (Guangzhou) Investment Group and Dr Michelle Chen, Chief Operating Officer, Biosyngen


The opening was officiated by Mr Alvin Tan, Minister of State for the Ministry of Trade and Industry, and executives from Biosyngen including Ms Joan Zhang, Chairman of Biosyngen, Prof Benjamin Seet, Board Member of Biosyngen, Dr Michelle Chen, Chief Operating Officer of Biosyngen and Prof Jean Paul Thiery, Chief Scientist of Biosyngen. The opening was also witnessed by distinguished guests from the Ministry of Health, Enterprise Singapore, Economic Development Board, SGX, A*STAR and National Cancer Centre Singapore (NCCS).

The new facility is the first and largest privately-owned, fully automatic, enclosed and integrated GMP cell manufacturing facility and Research & Development base in Singapore to date. The facility is compliant with the latest FDA (U.S. Food and Drug Administration) recommendation, enabling Biosyngen to run automatic and closed-system production – the preferred best practice in the CGT industry. Designed with containment within each production suite, this facility can support multiple clinical trials in parallel.

According to statistics from The Global Cancer Observatory (GCO), there were over five million deaths due to solid tumour cancers in Asia in 2020, accounting for 60% of the world's mortality rate.[1] Most solid tumours respond poorly to conventional cancer treatments such as chemotherapy.[2] Biosyngen's new GMP facility will leverage innovative capabilities to further the development of cutting-edge immunotherapies to improve treatment outcomes for such solid tumours.

"We started from humble beginnings in Singapore, renting a facility from Temasek Life Sciences Laboratory, and have now launched our new GMP facility. There is an urgency to increase speed in clinical trials for patients and build capacity for global needs, and Biosyngen is determined to take the lead in this space," said Dr Michelle Chen, Chief Operating Officer, Biosyngen.

Through years of extensive research, Biosyngen's first-in-class products targeting nasopharyngeal cancer (NPC) and EBV+ lymphoma were granted Investigative New Drug (IND) approval by the US FDA and China National Medical Products Administration (NMPA). Its product targeting NPC was also recently granted the status of Orphan Drug Designation (ODD). In June 2023, the company submitted IND applications for two other indications, lung cancer and liver cancer, to both the FDA and NMPA.

"Our facility in Singapore enables R&D in drug discovery and process development, and will also be able to accommodate more advanced processes or products that will be introduced in the future," added Dr Cecilia Zhang, Chief Scientific Officer, Biosyngen.

In Guangzhou China, Biosyngen also has the largest GMP cell production base in South China. Biosyngen has become the only immuno-oncology company in Asia with dual headquarters, dual fully automatic and enclosed GMP, and dual R&D layout. Biosyngen has achieved the simultaneous global development of innovative drugs and cost reduction of CGT drugs to the largest extent.

"We are a company dedicated to giving cancer patients a new lease of life by developing first-in-class immunotherapies. We aim to achieve this through our Research & Development (R&D) and collaborations with key stakeholders in hospitals, the wider industry and governments.
Having two sites, one in Singapore and China, is a key global strategy for Biosyngen to advance the company's product pipeline quicker, and drive R&D and GMP manufacturing from both sites," said Isaac Chow, Chief Business Officer, Biosyngen.

Earlier this week, the company signed an agreement to set up a China-Singapore Technology Innovation and Translational Medicine Centre for Tumour Prevention and Treatment as part of the Singapore-Guangdong Collaboration Council (SGCC).

Biosyngen is also working closely with stakeholders in the Singapore healthcare ecosystem, collaborating with the National Cancer Centre Singapore (NCCS) to conduct a basket of clinical trials for various cancer indications and biomarker discovery to enhance patient selection and effectiveness. In addition, the company has set up a joint lab with the Agency for Science, Technology and Research (A*STAR) to develop multi-specific antibodies targeting solid tumours. The company also works closely with the Advanced Cell Therapy and Research Institute (ACTRIS) to consult on GMP practices and process development.

Hashtag: #biosyngen #celltherapy #gmpfacility #immuno-oncology


The issuer is solely responsible for the content of this announcement.

About Biosyngen

With R&D powered by scientists from Singapore, China, Germany, Australia, France, and America, Biosyngen is dedicated to give cancer patients a second chance by developing first-in-class innovative immunotherapies. Aiming for the global market with dual R&D centers and GMP facilities set in Singapore and China, Biosyngen owns a product portfolio with potential global market of more than 50 billion USD.

Biosyngen possesses exclusive licenses and patented therapies targeting multiple solid tumors and hematological malignancies including nasopharyngeal cancer, gastric cancer, lymphoma and posttransplant lymphoproliferative disorders. We collaborate closely with the world's leading biomedical research and clinical institutes including A*STAR, Helmholtz Zentrum München, Hannover Medical School, Sun Yat-Sen University Cancer Center to advance our R&D process and conduct clinical trials in Singapore, Australia and China.

Utilizing our strong R&D capability and translational medicine platform, we have been able to engage the end-to-end cycle of drug development including lead identification, preclinical studies cell production and quality control, regulatory filing and clinical studies, thus integrating R&D, manufacturing and commercialization

News from Asia

XTransfer, VPBank and SmartPay Announce Partnership at Singapore FinTech Festival 2026

Empowering SMEs in Vietnam–China and Vietnam–ASEAN TradeSINGAPORE – Media OutReach Newswire – 19 November 2026 – XTransfer, the world's leading B2B cross-border trade payment platform, VPBank, a...

Columbia Asia Hospital Tebrau and Columbia Asia Hospital Iskandar Puteri jointly achieve Malaysia Book of Records recognition for their Mega Parenthood Workshop 2026

JOHOR BAHRU, MALAYSIA – Media OutReach Newswire – 19 November 2026 – Becoming a parent is one of life's most beautiful journeys, filled with excitement, questions and, at times, uncertainty. Recog...

Lambency Detailing becomes GTECHNIQ Accredited Detailer at both outlets and launches its new e-commerce website

Partnership brings GTECHNIQ’s accredited-only Crystal Serum Ultra to Ubi and Bukit Batok with a 10-year warranty; the new lambencydetailing.com launches the same day with online purchase and bookin...

Uthoppia House Founder Yusup Ngadimin Receives 2026 Spirit of Enterprise Start-up Award

Recognition marks a milestone in the Singapore AI company’s journey to help individuals and employers make more informed career and talent decisionsSINGAPORE– Media OutReach Newswire – 19 November...

UnionPay International Debuts Digital Trade Solution at CIIE 2026, Streamlining Cross-Border B2B Settlement for Global E-Commerce

SHANGHAI, CHINA – Media OutReach Newswire – 19 November 2026 — UnionPay International (UPI), together with Bank of China and Shanghai E&P International, today officially unveiled its Digital T...

DNA Brands Co Marks Fourth Anniversary, Building on Its Growth in Singapore’s Beauty and Wellness Industry

Celebrating four years of progress, the Singapore company looks to elevate its achievements through people, innovation and a shared passion for beauty and wellness as self-care becomes an increasin...

LittleLives, Little Lab and SEGi College Sign MOU to Explore Early Childhood Education Collaboration Across ASEAN

SUBANG JAYA, MALAYSIA - Media OutReach Newswire - 20 November 2026 – LittleLives, Little Lab and SEGi College signed a Memorandum of Understanding (MOU) on 5 November 2026 to explore collaboration...

Bosideng Marks 50 Years with ‘Warmth Code’ Exhibition in Shanghai

SHANGHAI, CHINA – Media OutReach Newswire – 20 November 2026 – Bosideng marked its 50th anniversary with 'Warmth Code: Half a Century of History', a landmark exhibition at Gate M West Bund Dream C...

Sixth Asia International Innovation and Invention Hong Kong Showcases Over 180 Innovations from the Asia-Pacific

Hong Kong Exporters’ Association’s “Hong Kong Innovation and Invention” Program exhibits at Entrepreneur Day for the fourth consecutive yearHONG KONG SAR – Media OutReach Newswire – 20 November 20...

Travel Insurance Was Built for the Few Who Claim. Ancileo’s Felt Coverage™ is for Everyone Else

There are now two kinds of travel insurance: coverage that’s contracted, and coverage that’s felt. Ancileo is the first to introduce the latter.SINGAPORE – Media OutReach Newswire – 20 November 20...

New Research Highlights What Australian Retailers Need to Deliver

New research among Australian SHEIN customers reveals how price comparisons, product quality and customer reviews are shaping purcha...

Why the secrecy around car insurance?

Every year, millions of Australians receive their car insurance renewal and promise themselves they’ll look at it properly later. Then life gets in ...

Australian workers spend almost an hour a day administering email

Research finds email filing, searching and rework consuming an estimated 58 minutes a day and potentially exposing organisations to millionsAustralian...

Customer Service Is Becoming Part of the Small Business Sales and Marketing Engine

For Customer Service Week, 5-9 October, Thryv is urging small businesses to look beyond generating  enquiries and examine what happens after a custome...

Gift Cards as the gateway to agentic payments

Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...

Why Data Accumulation Without Governance Undermines Sustainability Goals

In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...